The People Behind ARCHIMED

ARCHIMED's strength lies in the exceptional diversity of its team — over 160 professionals united by a shared passion for healthcare and a commitment to patient impact. Deliberately composed of one-third finance experts, one-third scientists, and one-third operational leaders, our team brings a rare combination of disciplines to every investment. We believe that the best outcomes for patients and investors come from people who truly understand healthcare from the inside.

Laurent Gauthier

Managing Partner & Co-Founder

Laurent co-founded ARCHIMED with a vision to bring genuine healthcare expertise to private equity. With a background spanning clinical research and corporate strategy, he has led the firm through four successive fund generations and built its reputation as Europe's leading healthcare specialist investor.

Sophie Reinholt

Partner, Scientific Affairs

Sophie leads ARCHIMED's scientific due diligence and post-investment R&D support, drawing on over two decades of experience in pharmaceutical development and regulatory strategy. She is a key architect of the firm's integrated team model and a frequent advisor to portfolio company boards.

Marcus Delacroix

Partner, Investments

Marcus oversees deal origination and execution across ARCHIMED's European and global investment activities. He has led several of the firm's most significant transactions, including complex cross-border buyouts and take-private processes in the biopharmaceutical sector.

Ingrid Voss

Operating Partner

Ingrid brings 25 years of operational leadership in healthcare services and medtech to ARCHIMED's portfolio support function. She works directly with portfolio company management teams to accelerate commercial growth, build leadership capacity, and drive strategic transformation.

Thomas Karamanlis

Chief Financial Officer

Thomas manages ARCHIMED's fund administration, investor relations, and financial reporting across all fund vehicles. He has played a central role in the successful fundraising of MED III and MED IV, building trusted relationships with leading institutional limited partners worldwide.